Youve heard of the popular glucagon-like peptide-1 (GLP-1) receptor agonist drug semaglutide (Ozempic, Wegovy) and GLP-1/GIP drug tirzepatide (Mounjaro, Zepbound). Now theres a new kid on the weight ...

Retatrutide is an new drug that has shown promise in the treatment of obesity and type 2 diabetes. Retatrutide is a type of multi-receptor agonist that targets multiple hormonal pathways involved in ...

iPercent change in the WOMAC pain subscale score and percent change in the WOMAC physical function subscale score were not pre-specified and were estimated from a post-hoc analysis.iiNot controlled ...

TRANSCEND-T2D-1 trial findings indicate that retatrutide provides significant improvements in HbA1c and cardiovascular risk factors. Topline results were announced from a phase 3 trial evaluating ...

Retatrutide (LY3437943) is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors. Its dose–response relationships with respect to side effects ...

Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The ...

Add Futurism (opens in a new tab) More information Adding us as a Preferred Source in Google by using this link indicates that you would like to see more of our content in Google News results.

GLP-1 has become a popular buzzword in the weight-loss community — but now some are touting "GLP-3s," claiming they are taking obesity medications to the next level. GLP-1 (glucagon-like peptide-1) ...

TUCSON, AZ / ACCESS Newswire / February 9, 2026 / Umbrella Labs today announced an expanded research focused program for retatrutide peptide to support laboratories running multi receptor signaling ...

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or ...